KOCAA
Knights of Columbus Asset Advisors’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,911
| Closed | -$2.85M | – | 383 |
|
|
2024
Q4 | $2.85M | Sell |
20,911
-1,309
| -6% | -$179K | 0.19% | 147 |
|
|
2024
Q3 | $2.56M | Sell |
22,220
-24,833
| -53% | -$2.86M | 0.17% | 160 |
|
|
2024
Q2 | $6.48M | Buy |
47,053
+485
| +1% | +$66.8K | 0.42% | 65 |
|
|
2024
Q1 | $6.42M | Buy |
46,568
+374
| +0.8% | +$51.6K | 0.46% | 54 |
|
|
2023
Q4 | $6.09M | Sell |
46,194
-1,502
| -3% | -$198K | 0.39% | 78 |
|
|
2023
Q3 | $5.37M | Buy |
47,696
+17,414
| +58% | +$1.96M | 0.49% | 52 |
|
|
2023
Q2 | $2.86M | Buy |
30,282
+10,163
| +51% | +$958K | 0.26% | 121 |
|
|
2023
Q1 | $2.04M | Buy |
20,119
+16,945
| +534% | +$1.72M | 0.2% | 174 |
|
|
2022
Q4 | $379K | Buy |
+3,174
| New | +$379K | 0.04% | 264 |
|
|
2021
Q2 | – | Sell |
-17,146
| Closed | -$1.67M | – | 330 |
|
|
2021
Q1 | $1.67M | Buy |
17,146
+554
| +3% | +$53.9K | 0.16% | 206 |
|
|
2020
Q4 | $1.59M | Sell |
16,592
-10,428
| -39% | -$999K | 0.17% | 216 |
|
|
2020
Q3 | $2.6M | Buy |
27,020
+4,721
| +21% | +$454K | 0.32% | 107 |
|
|
2020
Q2 | $2.72M | Buy |
+22,299
| New | +$2.72M | 0.33% | 99 |
|